Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating... see more

Recent & Breaking News (NDAQ:BOLT)

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

GlobeNewswire May 14, 2024

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 21, 2024

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire February 27, 2024

Pacira Appoints Frank D. Lee as Chief Executive Officer

GlobeNewswire December 21, 2023

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

GlobeNewswire December 5, 2023

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 9, 2023

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

GlobeNewswire November 7, 2023

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

GlobeNewswire October 23, 2023

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting

GlobeNewswire October 18, 2023

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

GlobeNewswire October 17, 2023

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

GlobeNewswire October 16, 2023

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

GlobeNewswire September 28, 2023

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

GlobeNewswire September 12, 2023

Bolt Biotherapeutics to Participate in September Investor Conferences

GlobeNewswire September 5, 2023

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 7, 2023

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

GlobeNewswire August 3, 2023

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

GlobeNewswire July 31, 2023

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

PR Newswire May 30, 2023

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

GlobeNewswire May 25, 2023

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023